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RNA interference (RNAi) is a well-conserved mechanism that uses small noncoding RNAs to silence gene
expression posttranscriptionally. Gene regulation by RNAi is now recognized as one of the major regulatory
pathways in eukaryotic cells. Although the main components of the RNAi/miRNA pathway have been identi-
fied, the molecular mechanisms regulating the activity of the RNAi/miRNA pathway have only begun to
emerge within the last couple of years. Recently, high-throughput reporter assays to monitor the activity
of the RNAi/miRNA pathway have been developed and used for proof-of-concept pilot screens. Both inhib-
itors and activators of the RNAi/miRNA pathway have been found. Although still in its infancy, a chemical
biology approach using high-throughput chemical screens should open up a new avenue for dissecting
the RNAi/miRNA pathway, as well as developing novel RNAi- or miRNA-based therapeutic interventions.Introduction
Increasingly complex networks of small RNAs act through RNA
interference (RNAi) pathways to regulate gene expression in
simple multicellular organisms to humans. RNAi is a well-
conserved mechanism in which small regulatory RNAs silence
gene expression posttranscriptionally (Bartel, 2004; Hannon,
2002). Gene regulation by RNAi has been recognized as one of
the major regulatory mechanisms in eukaryotic cells (Plasterk,
2006). Small regulatory RNAs, including microRNAs (miRNAs),
endogenous small interfering RNAs (esiRNAs), Piwi-interacting
RNAs (piRNAs), and promoter-associated sRNAs (PASRs, or
transcription initiation RNAs [tiRNAs]), are 18–30 nucleotides in
length and can shape diverse cellular pathways, from chromo-
some architecture, development, and growth control to apo-
ptosis and stem cell maintenance (Table 1) (Czech et al., 2008;
Ghildiyal and Zamore, 2009; Kawamura et al., 2008; Kim et al.,
2009; Okamura et al., 2008; Okamura and Lai, 2008; Plasterk,
2006; Taft et al., 2009). Mounting evidence suggests that the
misregulation of miRNAs could contribute to the pathogenesis
of a wide range of human diseases. Moreover, the RNAi mecha-
nism has been adopted by researchers and is of broad utility in
gene-function analysis, drug-target discovery and validation,
and therapeutic development (Dykxhoorn and Lieberman,
2005, 2006). Given the pivotal roles of miRNAs in diverse biolog-
ical pathways and human disease as well as the broad applica-
tion of RNAi, understanding the mechanism of the RNAi/miRNA
pathway is essential.
Although the major components within the RNAi/miRNA
pathway have been identified, the molecular mechanisms
regulating the activity of the RNAi/miRNA pathway have only
begun to emerge within the last couple of years. Chemical
biology, in particular the use of diverse chemicals to interrogate
molecular processes, provides a novel means of rapidly and
effectively dissecting biological mechanisms and gene networks
in ways not feasible with mutation-based genetic approaches
(Hergenrother, 2006; Lipinski and Hopkins, 2004; Schreiber,
2005). Unlike the traditional genetic approach, wherein nucleo-584 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigtide changes (mutations) are fixed, chemical biology offers
a more dynamic way to monitor and study the activity of specific
pathways. Thus, identification of the small molecules modulating
the biological activity of the RNAi pathway will allow us to explore
miRNA/siRNA biogenesis from a unique angle that could open
up a whole new approach for dissecting the RNAi/miRNA path-
way, as well as developing novel therapeutic interventions.
Although a chemical biology approach to the RNAi/miRNA
pathway is still in its infancy, with assays just in place and only
a handful of screens being run, we highlight, in this article, recent
discoveries of small-molecule modulators of the RNAi/miRNA
pathway, which illustrate how a chemical biology approach
could be used to dissect the RNAi/miRNA pathway.
The RNAi/miRNA Pathway and Its Regulation
Over the last several years, research has uncovered key protein
components involved in the RNAi/miRNA pathway (Figure 1).
In mammals, the majority of endogenous miRNA genes are tran-
scribed initially as primary transcripts (pri-miRNAs) that range
from hundreds to thousands of nucleotides (nt) in length and
contain one or more extended hairpin structures (Du and Zamore,
2005). The nuclear RNase III enzyme Drosha, working with
DGCR8, cleaves both strands near the base of the primary
stem-loop and yields the precursor miRNA (pre-miRNA), an
65 nt stem-loop that harbors the miRNA in the 50 or 30 half of
the stem (Lee et al., 2003). The cleavage by Drosha defines one
end of the mature miRNA and generates a 50 phosphate and an
2 nt 30 overhang (Du and Zamore, 2005). However, recent
studies have also identified short hairpin introns, called ‘‘mir-
trons,’’ that provide an alternative source for microRNA biogen-
esis (Berezikov et al., 2007; Okamura et al., 2007; Ruby et al.,
2007). Mirtrons use the splicing machinery to bypass Drosha
cleavage in initial maturation to produce pre-miRNAs. After being
exported to the cytoplasm by exportin-5/RanGTP, pre-miRNAs
are further cleaved by the RNase III Dicer along with a dsRNA-
binding protein, TAR RNA-binding protein (TRBP), to define the
other end of the mature miRNA and produce the double-strandedhts reserved
Table 1. Types of Endogenous Small Regulatory RNAs
Definition
MicroRNA (miRNA) 18- to 25-nucleotide noncoding RNAs that
can regulate translation of target mRNA
molecules in a sequence-specific manner.
Endogenous small
interfering RNAs
(esiRNAs)
Endogenous siRNA derived from
bidirectional transcripts or the transcript of
an inverted repeat.
Piwi-interacting
RNAs (piRNAs)
26- to 31-nucleotide noncoding RNAs
associated with Piwi-subfamily proteins.
Most piRNAs are mapped to the repetitive
regions of the genome and thought to
control the activity of transposons.
Promoter-associated
sRNAs (PASRs, or
transcription initiation
RNAs [tiRNAs])
Small RNAs mapped to the 50-end or
promoter region of the protein-coding
genes that are proposed to have a role in
divergent transcription.
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complex is also required for the processing of short hairpin
RNA (shRNA) into small interference RNA (siRNA) of 21 bp
(Zamore and Haley, 2005). After cleavage by Dicer andFigure 1. The RNAi/miRNA Pathway
Genes encoding microRNAs are initially transcribed by RNA polymerase II or III
to generate the primary miRNA transcripts (pri-miRNA) within the nucleus. The
stem-loop structure of the pri-miRNA is recognized and cleaved on both
strands by a Microprocessor complex, which consists of the nuclear RNase
III enzyme Drosha and an RNA-binding protein, DGCR8, to yield a precursor
miRNA (pre-miRNA) 60-70 nucleotides in length. The pre-miRNA is then
exported from the nucleus through a nuclear pore by exportin-5 in a Ran-
GTP-dependent manner and processed in the cytoplasm by the RNase III
Dicer-TRBP. Sliced RNA strands are further unwound. One strand of the
miRNA/miRNA* or siRNA duplex (the antisense, or guide strand) is then pref-
erentially incorporated into the RNA-induced silencing complex (RISC) and
will guide the RISC to a target mRNA in a sequence-specific manner. Once
directed to a target mRNA, the RISC can mediate translational regulation by
inhibiting the initiation or the elongation step or through destabilization of the
target mRNA. The illustrated number of base pairs does not reflect the actual
length of either miRNA or siRNA.
Chemistry & Biunwinding, one strand of the miRNA/miRNA* or siRNA duplexes
(the antisense, or guide strand) is then preferentially incorporated
into the RNA-induced silencing complex (RISC), while the other
strand (the sense, or passenger strand) is degraded (Zamore
and Haley, 2005). The RISC is a large and heterogeneous multi-
protein complex. The core components of the RISC include
Dicer, TRBP, and Argonaute 2 protein (AGO2); of these, AGO2,
which was identified as the sole protein required for mRNA-
cleaving RISC activity (Slicer activity), is the key RISC component
(Figure 1) (Liu et al., 2004; Rand et al., 2004; Rivas et al., 2005).
The assembly and function of RISC complex can be divided
into at least two catalytically controlled steps (Rana, 2007).
The first kinetic checkpoint involves the loading of small RNAs
onto RISCs. Dicer along with TRBP can process both shRNAs
and pre-miRNAs into an 21-nt RNA helix, on which RISC is
assembled (Zamore and Haley, 2005). The passenger strand is
cleaved by AGO2 and destroyed, and the guide strand is incorpo-
rated into the RISC to become active RISC (Leuschner et al.,
2006; Matranga et al., 2005; Rand et al., 2005). The process of
RISC loading is found to be influenced by the thermodynamics
of the RNA duplex (Khvorova et al., 2003; Reynolds et al., 2004;
Schwarz et al., 2003). The second step involves target recogni-
tion and cleavage by AGO2. RISC finds its mRNA target, cleaves
the mRNA, and is recycled for potential additional cleavage. The
kinetics of this step can be modulated by the target mRNA struc-
ture, structural reorganization of RISC, and product release
(Rana, 2007). The protein components of RISC can also modulate
the activity of RISC, particularly at these two checkpoints.
As key regulators in cellular functions, miRNAs themselves are
shown to be tightly controlled at multiple levels. First, at the tran-
scriptional level, transcription factors can directly regulate the
expression of specific miRNAs, while specific miRNAs can
then target another transcription factor and regulate its expres-
sion posttranscriptionally, resulting in a transcription factor—to
miRNA—to another transcription factor (sometimes even of the
miRNA itself) paradigm for gene regulation (Gangaraju and Lin,
2009). This represents a novel evolutionarily conserved strategy
to maintain the balance between the miRNAs and their transcrip-
tional regulatory programs. Second, miRNA processing, pri- to
pre-miRNAs and pre- to mature miRNAs, can be regulated as
well. Lin28, a developmentally regulated RNA-binding protein,
was found to selectively block the processing of pri-let-7
miRNAs in embryonic cells by competing for binding to con-
served nucleotides in the loop region of the let-7 precursor
(pre-let-7) and inducing uridylation of pre-let-7 (Newman et al.,
2008; Viswanathan et al., 2008). A noncanonical poly (A) poly-
merase, TUTase4 (TUT4), was identified as the uridylyl trans-
ferase involved in this process (Hagan et al., 2009; Heo et al.,
2008, 2009). Furthermore, the KH-type splicing regulatory
protein (KSRP, also known as KHSRP), a previously identified
mediator of mRNA decay, was found to bind with high affinity
to the terminal loop of the selective miRNA precursors and
promotes their maturation (Trabucchi et al., 2009). These find-
ings suggest that, besides the general components involved,
other proteins could be involved in the efficient processing of
specific miRNAs. Finally, posttranslational modifications can
also regulate the activities of the core RISC factors. It was found
that TRBP could be phosphorylated in response to Erk pathway
activity (Paroo et al., 2009). Phosphorylation of TRBP enhancesology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 585
Table 2. Small-Molecule Modulators of the RNAi/miRNA Pathway Identified via Chemical Screens
Small Molecule Chemical Structure Function and Target Reference
ATP analogs:
ATPA-18 (left) and
ATPA-21 (right)
RNAi inhibitor, targets
an early unwinding
step in the RNAi
pathway, possibly
an ATP-dependent
RNA helicase.
Chiu et al., 2005
Enoxacin RNAi activator, targets
TRBP and facilitates the
interaction between
TRBP and RNA
Shan et al., 2008
miR-21 Inhibitor Specific inhibitor of
miR-21, targets the
transcription of miR-21
Gumireddy et al.,
2008
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Minireviewits stability as well as that of its partner, Dicer, which increases
the steady level of miRNA processing complex (Paroo et al.,
2009). Furthermore, the hydroxylase C-P4H (I) was also shown
to catalyze hydroxylation of Ago2 (Qi et al., 2008). Proline
hydroxylation stabilizes the Ago2 protein, facilitating small
RNA-guided mRNA cleavage (Qi et al., 2008). In addition, Ago2
could be phosphorylated via the p38 MAPK pathway (Zeng
et al., 2008). Both the phosphorylation and hydroxylation
enhance Ago2 localization to the P-body, though the physiolog-
ical significance of P-body localization is unclear. These findings
illustrate the different regulatory mechanisms of miRNA biogen-
esis and function, which could serve as potential targets for
modulating the activity of the RNAi/miRNA pathway with small
molecules.
Small Molecules Modulating the Activity
of the RNAi/miRNA Pathway
The key step in any small molecule-based screen is the develop-
ment of a reliable and robust assay, and both in vitro and in vivo
assays have now been created. An in vitro fluorescence assay
has been developed to measure the activity of Dicer (Davies
and Arenz, 2006). In this assay, based on the pre-miRNA
sequence of let-7, an RNA hairpin with a fluorescence emitter
at the 50 terminus and a fluorescence quencher at the 30 terminus
was prepared. Due to the close proximity of the fluorophore and
the quencher, no fluorescence is detected in the case of an intact
hairpin. Thus, the cleavage activity of Dicer can be measured by
the increase of fluorescence signal. However, the application of
this assay to small molecule screens has yet to be evaluated.
The in vivo assay was developed initially by transient cotrans-
fection of EGFP-expressing plasmid and siRNA against EGFP
(Chiu et al., 2005). In this assay, plasmids harboring enhanced
green- and red-fluorescent proteins (EGFP and RFP, respec-
tively) are cotransfected into HeLa cells with EGFP siRNA that
targets EGFP mRNA for degradation. The ratio of EGFP/RFP
fluorescence in the presence of siRNA is calculated and normal-
ized to the EGFP/RFP ratio of mock-treated cells. Given the
multiple ATP-dependent steps of the loading of the siRNA586 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigduplex onto active RISC, a small chemical library of substituted
dihydropteridinones as ATP analogs that contain both rigid and
flexible scaffolds was used for this screen; two nontoxic
compounds (ATPA-18 and ATPA-21) that specifically inhibit
ATP-dependent events during RNAi were found (Table 2)
(Chiu et al., 2005). A series of in vitro and in vivo analyses
demonstrate that these compounds specifically affect an early
unwinding step in the RNAi pathway, suggesting that its target
is an ATP-dependent RNA helicase, although the precise molec-
ular target remains a mystery (Chiu et al., 2005). Interestingly,
these compounds had no effect on the endogenous miRNA
pathway. These results establish the timing of siRNA unwinding
and suggest that siRNA helicase activity is required for RNAi.
In our own studies, we found that transient transfections with
the DNA plasmid and the siRNA duplex have variable efficacy,
making them unsuitable for future high-throughput screening.
To address this problem, we developed a RNAi reporter system
in which both an EGFP protein and an shRNA against EGFP are
stably expressed (Figure 2) (Shan et al., 2008). In addition, select-
ing the proper cell clone for the chemical screen is also critical.
Although the use of a clone with a strong knockdown of EGFP
would have enabled us to identify inhibitors of the RNAi pathway
robustly (EGFP expression would increase if the RNAi pathway
were inhibited), it would nevertheless offer little chance of finding
any small molecules that could enhance RNAi. We therefore
chose to use a specific clone with a modest EGFP knockdown,
thereby enabling us to identify both inhibitors and enhancers
(Figure 2). Using this assay, we performed a proof-of-principal
pilot screen with a collection of 2000 FDA-approved compounds
and natural products and showed that the small molecule
enoxacin enhances RNA interference induced by either shRNAs
or siRNA duplexes and significantly reduces the siRNA dosage
required to achieve gene knockdown in mammalian cells
(Table 2) (Shan et al., 2008). Enoxacin was identified as an
RNAi enhancer in an independent chemical screen from another
group as well (Zhang et al., 2008). Enoxacin belongs to a family of
synthetic antibacterial compounds based on a fluoroquinolone
skeleton (Bhanot et al., 2001). A study of structure-activityhts reserved
Figure 2. Development of a Reporter System to Monitor the Activity of the RNAi Pathway
Human 293 cells stably expressing EGFP (293-EGFP) were infected with lentivirus producing shRNA against EGFP (shRNA-EGFP); the resulting RNAi-293-EGFP
cells with reduced GFP expression were isolated. The RNAi-293-EGFP cells transfected with 2-O-methyl RNA against the GFP siRNA are shown on the right with
the recovery of GFP expression. The RNAi-293-EGFP cells could be used for a chemical screen to identify both inhibitors and enhancers of the RNAi pathway.
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enoxacin does not depend on general fluoroquinolone activity
but rather on the unique chemical structure of enoxacin (Shan
et al., 2008). Besides enhancing RNAi, enoxacin can also pro-
mote the biogenesis of endogenous miRNAs. Using a series of
in vitro and in vivo analyses, we found that the enoxacin-medi-
ated RNAi-enhancing activity is TRBP-dependent, and enoxacin
could facilitate the interaction between TRBP and RNAs (Shan
et al., 2008). Furthermore, we found that enoxacin had no effect
on an in vitro RISC-cleavage assay, which argues against the
potential involvement of enoxacin in the step of mRNA-target
recognition and cleavage. Rather, these results together suggest
that enoxacin targets the step of RISC loading by enhancing the
interaction between TRBP and RNAs. Although the previous
studies demonstrated the role of TRBP in the processing and
loading of miRNAs/siRNAs onto the RISC, our findings reveal
that TRBP plays important roles in modulating the activity or
efficacy of siRNAs, and one could potentially increase RISC-
loading efficiency and enhance RNAi by targeting TRBP-RNA
interactions (Chendrimada et al., 2005; Fo¨rstemann et al.,
2005; Jiang et al., 2005). Our findings also underscore the power
of chemical biology, through which we could monitor the
dynamic modulation of the RNAi pathway. It would have been
quite a challenge to uncover this modulation using traditional
genetic or biochemical approaches.
Besides unbiased chemical screens using different reporter
systems, small molecules that modulate the activity of the
RNAi/miRNA pathway could also be developed based on our
understanding of RNAi/miRNA pathway regulation. As discussed
above, both Ago2 and TRBP can be phosphorylated. Thus, inhib-
itors of specific kinases that phosphorylate these proteins couldChemistry & Bipotentially be used to modulate the activity of the RNAi/miRNA
pathway as well (Paroo et al., 2009; Zeng et al., 2008). However,
those inhibitors are unlikely to specifically target the RNAi/miRNA
pathway, since the identified kinases are well known to be
involved in the regulation of many other biological pathways.
Small Molecules Modulating the Activity
of Specific miRNAs
A similar screening strategy can also be developed for individual
miRNAs. There is a luciferase-based screen system for miR-21,
which has been directly linked to several human malignancies
and may make a promising new target for the development of
cancer therapeutics (Krichevsky and Gabriely, 2009). In this
assay, the luciferase-miRNA complementary sequence plasmid
serves as a sensor to detect the presence of specific mature
miRNA. More importantly, this assay monitors the endogenous
miR-21 in transfected cells, which is not biased toward or against
any specific components of the miRNA pathway. Through
a primary screen of > 1200 compounds, a compound with the
diazobenzene core structure was discovered to inhibit the
suppression mediated by miR-21 (Gumireddy et al., 2008).
A further screen of 100 structurally modified molecules related
to the diazobenzene core structure led to the identification of
a highly active compound (Table 2, miR-21 inhibitor-right)
(Gumireddy et al., 2008). Interestingly, this compound is not
a general inhibitor of the miRNA pathway but displays specificity
for miR-21. Additional molecular analyses suggest that this
compound is a selective inhibitor by targeting the transcription
of the miR-21 gene, but not the downstream processes of the
common miRNA pathway. However, the exact cellular target of
this miR-21 inhibitor is still unknown.ology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 587
Chemistry & Biology
MinireviewFuture Perspectives on Chemical Biology Approaches
to the RNAi/miRNA Pathway
Through proof-of-concept pilot screens of limited numbers of
small molecules, small-molecule modulators targeting specific
steps in the RNAi/miRNA pathway have been identified. There-
fore, it would be interesting to use the existing reporter systems
to expand the screening to more comprehensive large-scale
compound libraries containing hundreds of thousands of com-
pounds with diverse scaffolds. Once small molecules capable
of modulating the activity of the RNAi/miRNA pathway are iden-
tified, a multidisciplinary approach that integrates chemical
synthesis, proteomics, biochemistry, and genetics should be
adopted to understand how the identified molecules modulate
the RNAi/miRNA pathway. Since a wide variety of chemical
structures would enable us to probe many classes of potential
targets, besides identifying small molecules targeting known
components within the RNAi/miRNA pathway, large-scale
chemical screens might reveal novel components of the RNAi/
miRNA pathway, a feat not easily achieved by way of traditional
forward and reverse genetic screens. Although this chemical
biology or chemical genetic approach is indeed very powerful,
there are some limitations that should be considered as well.
Despite significant progress in proteomics recently, it is still
a technical challenge to identify proteins specifically affected
by novel small molecules. Small molecules, even well-character-
ized ones, might have multiple targets that could give rise to the
observed modulation. After the identification of candidate
protein targets, additional studies using other molecules target-
ing the same protein(s) and genetic experiments are necessary.
Although all the miRNAs in the genome use the same pathway
to process pri-miRNAs to produce the functional mature
miRNAs, we are now aware that miRNAs can be differentially
processed in a given cell, and a given miRNA can be processed
differently in different cell types (Thomson et al., 2006; Viswana-
than et al., 2008). The mechanism underlying the regulation of
miRNA processing has yet to be determined. Uncovering this
mechanism is particularly important for those miRNAs that
have been linked to human diseases and could serve as new
therapeutic targets. Therefore, identifying small molecules that
can modulate the activity of specific miRNAs is key. Although
this may pose a significant challenge to chemical biology, its
feasibility has been demonstrated by the identification of the
miR-21 inhibitor (Gumireddy et al., 2008). Besides potentially
targeting the protein(s) involved in the regulation of the process-
ing of selective miRNAs, several small molecules have been
reported to bind directly to RNAs, including miRNAs (Gooch
and Beal, 2004; Henn et al., 2008; Thomas and Hergenrother,
2008; Tor, 2003). Through screening of a library of 7680
N-substituted oligoglycines (peptoids), specific ligands for the
RNA hairpin precursor of miR-21 were identified; however,
whether these ligands affect miRNA processing remains to be
determined (Chirayil et al., 2009). Given the differences in RNA
secondary structure among different miRNA precursors, it is
likely that small molecules targeting specific pri-, pre-, or mature
miRNA will be found.
Since miRNAs play major roles in nearly every cellular process,
the identification and characterization of small-molecule modula-
tors of the RNAi/miRNA pathway will yield fresh insights into
fundamental mechanisms behind human disease. By studying588 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigthe mode of action of these small-molecule modulators and iden-
tifying their protein targets, we could learn more about the
dynamic regulation of the miRNA pathway and uncover additional
factors that modulate the activity of the miRNA pathway. These
small molecules could also be used to modulate the kinetics of
specific step(s) in the miRNA pathway or specific miRNAs both
experimentally and for therapeutic purposes. Moreover, these
RNAi modulators, particularly RNAi enhancers, could potentially
facilitate the development of RNA interference as a tool for
biomedical research and therapeutic interventions. Although
this field is still in its infancy, given the progress that has already
been made and the widespread use of small molecule probes tar-
geted to specific proteins, small-molecule RNAi modulators are
likely to show their true potential in the very near future.
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Note Added in Proof
Most recently, two compounds that could suppress RNAi activity in cultured
cells were identified and characterized; one could impair Dicer activity, while
the other blocks small RNA loading into an Argonaute 2 complex (Watashi,
K., Yeung, M.L., Starost, M.F., Hosmane, R.S., and Jeang, K.T. (2010). Identi-
fication of small molecules that suppress microRNA function and reverse
tumorigenesis. J. Biol. Chem., in press. Published online June 7, 2010.
10.1074/jbc.M109.062976.). In addition, the first small molecule inhibitors
and activators of the liver-specific microRNA miR-122 were also reported
(Young, D.D., Connelly, C.M., Grohmann, C., and Deiters, A. Small molecule
modifiers of microRNA miR-122 function for the treatment of the hepatitis
C virus infection and hepatocellular carcinoma. J. Am. Chem. Soc. 132,
7976–7981).ology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 589
